Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer
Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer
复制标题
DOI：
10.1001/archsurg.2011.795
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Lieto, Eva
中科院分区：
文献类型：
--
作者：
Galizia, Gennaro;Gemei, Marica;Lieto, Eva
假设：由于传统的人类结直肠癌发生模型存在一些不一致之处，最近提出了癌症干细胞（CSC）模型，其中肿瘤是干细胞肿瘤转化为CSC的结果。通过表面抗原的表达来鉴定 CSC 仍然是一个关键问题，因为没有生物标志物被证明是完全可靠的。 CD133 和 CD44 通常用作 CSC 标志物，它们的表达与结直肠癌 (CRC) 临床病理特征和结果的相关性可能有用。设计：试点研究。地点：大学医院。患者：36 名连续的 CRC 患者。通过流式细胞术测定非肿瘤细胞和肿瘤细胞中的 CD133 和 CD44 表达（单独或组合），流式细胞术仅鉴定活细胞。主要结果指标：CD133 和 CD44 表达彼此之间、与其他预后指标以及无病生存的相关性。结果：CD133 和 CD44 表达在肿瘤细胞中显着高于非肿瘤细胞，并且其中一种的表达与非肿瘤细胞的表达不一定相关。其他。 CD133 或 CD44 单独表达是可变的，而 CD133/CD44 组合表达则鉴定出一小部分 CRC 阳性细胞。 CD133 或 CD44 过表达与 CRC 复发无关；只有高频率的 CD133(+)/CD44(+) 细胞才是较差无病生存率的有力指标，也是 CRC 复发的独立危险因素。结论：CD133/CD44 联合表达的评估可有助于识别假定的结直肠 CSC 和预后不良的肿瘤。拱门外科。 2012年； 147(1)：18-24
Hypothesis: Because of some inconsistencies in the traditional model of human colorectal carcinogenesis, the cancer stem cell (CSC) model was recently proposed, in which tumor results from neoplastic transformation of stem cells, which become CSCs. Identification of CSCs by expression of surface antigens remains a critical issue because no biomarker has been shown to be completely reliable. CD133 and CD44 are commonly used as CSC markers, and correlation of their expression with colorectal cancer (CRC) clinicopathological features and outcomes may be useful.Design: Pilot study.Setting: University hospital.Patients: Thirty-six consecutive patients with CRC. CD133 and CD44 expression (alone or combined) was determined in nontumor cells and in tumor cells by flow cytometry, which identified viable cells only.Main Outcome Measures: Correlation of CD133 and CD44 expression with each other, with other prognostic indicators, and with disease-free survival.Results: CD133 and CD44 expression was significantly higher in tumor cells than in nontumor cells, and expression of one did not necessarily correlate with expression of the other. CD133 or CD44 expression alone was variable, while combined CD133/CD44 expression identified a small subset of cells positive for CRC. CD133 or CD44 overexpression was not associated with CRC recurrence; only high frequencies of CD133(+)/CD44(+) cells were a strong indicator of worse disease-free survival and an independent risk factor for CRC recurrence.Conclusion: Evaluation of combined CD133/CD44 expression could be useful to identify putative colorectal CSCs and tumors with a poor prognosis. Arch Surg. 2012; 147(1): 18-24